Gilead Sciences (GILD) has accused the U.S. government of breaching several contracts and “secretly” obtaining patents stemming from research that led to the ground-breaking Truvada HIV-prevention pill.
In a lawsuit filed late Friday, the drug maker claimed the Centers for Disease Control and Prevention violated the terms of a 15-year-old collaboration by failing to notify the company of patents that were later sought and awarded on the research.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
What is it?
STAT Plus is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
